Description
Recombinant monoclonal antibody to CD23. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the monkey B cell clone IDEC-152 (Lumiliximab, 6G5) . This chimeric mouse antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Target
CD23
Target Alias Names
Gomiliximab, FCER2, BLAST-2, FcεRII, Fc-epsilon-RII, Low affinity immunoglobulin epsilon Fc receptor, C-type lectin domain family 4 member J, Immunoglobulin E-binding factor, Lymphocyte IgE receptor
Isotype/Mimetic
IgG2b
Animal-Derived Biomaterials Used
No
Sequence Available
No
Original Discovery Method
recombinantly reformatted hybridoma (from pre-2020 immunisation)
Original Discovery Information Provided On Datasheet
Yes
Antibody/Binder Origins
Animal-dependent discovery (in vitro display, OR immunisation pre-2020), In vitro recombinant expression